CDK20 and breast cancer: Clinically, analyzing expression by IHC on 170 primary tumor samples of ER+ve breast cancer patients who received DOX neoadjuvant/adjuvant chemotherapy, we observed a positive correlation between high BQ, AR, and CCRK expression, which correlated with poorer prognosis, as well as DOX resistance (Figure 9), in keeping with our previous findings reporting the role of BQ in epirubicin and anastrozole resistance [32,33].